Abbott ID Now COVID-19 快速核酸检测在纽约学术机构的性能评估
本研究比较了Abbott ID Now COVID-19与Cepheid Xpert Xpress SARS-CoV-2两种核酸检测平台。结果显示,无论采用病毒运输介质中的鼻咽拭子还是干鼻拭子,Abbott ID Now对Cepheid阳性样本的检出率均较低,分别有三分之一和45%的样本呈阴性。
要点
- Abbott ID Now在鼻咽拭子(病毒运输介质)中漏检约三分之一Cepheid阳性样本。
- Abbott ID Now在干鼻拭子中漏检45%的Cepheid阳性样本。
- 两种平台性能差异提示Abbott ID Now阴性结果需谨慎解读。
核心结论
- Abbott ID Now COVID-19 在鼻咽拭子(病毒运输介质)和干鼻拭子中,对Cepheid Xpert Xpress SARS-CoV-2阳性样本的检出率均较低。
研究设计与样本
- 在纽约学术机构实验室中,比较Abbott ID Now COVID-19与Cepheid Xpert Xpress SARS-CoV-2两种实时RT-PCR平台。
- 使用病毒运输介质中的鼻咽拭子(两种平台均用)和干鼻拭子(仅Abbott ID Now用)进行检测对比。
主要发现
- Abbott ID Now在病毒运输介质鼻咽拭子样本中,对Cepheid阳性样本有三分之一的检测结果为阴性。
- Abbott ID Now在干鼻拭子样本中,对Cepheid阳性样本有45%的检测结果为阴性。
临床怎么用
- 临床使用Abbott ID Now时,阴性结果不能完全排除SARS-CoV-2感染,需结合其他检测或临床判断。
局限性
- 研究仅比较了两种平台,未评估其他因素对性能的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The recent emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has posed formidable challenges for clinical laboratories seeking reliable laboratory diagnostic confirmation. The swift advance of the crisis in the United States has led to Emergency Use Authorization (EUA) facilitating the availability of molecular diagnostic assays without the more rigorous examination to which tests are normally subjected prior to FDA approval. Our laboratory currently uses two real-time reverse transcription-PCR (RT-PCR) platforms, the Roche Cobas SARS-CoV2 and the Cepheid Xpert Xpress SARS-CoV-2. The two platforms demonstrate comparable performances; however, the run times for each assay are 3.5 h and 45 min, respectively. In search for a platform with a shorter turnaround time, we sought to evaluate the recently released Abbott ID Now COVID-19 assay, which is capable of producing positive results in as little as 5 min. We present here the results of comparisons between Abbott ID Now COVID-19 and Cepheid Xpert Xpress SARS-CoV-2 using nasopharyngeal swabs transported in viral transport media and comparisons between Abbott ID Now COVID-19 and Cepheid Xpert Xpress SARS-CoV-2 using nasopharyngeal swabs transported in viral transport media for Cepheid and dry nasal swabs for Abbott ID Now. Regardless of method of collection and sample type, Abbott ID Now COVID-19 had negative results in a third of the samples that tested positive by Cepheid Xpert Xpress when using nasopharyngeal swabs in viral transport media and 45% when using dry nasal swabs.
引用
- Basu A, Zinger T, Inglima K, et al. Performance of Abbott ID Now COVID-19 Rapid Nucleic Acid Amplification Test Using Nasopharyngeal Swabs Transported in Viral Transport Media and Dry Nasal Swabs in a New York City Academic Institution. J Clin Microbiol. 2020. PMID: 32471894. doi:10.1128/JCM.01136-20
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。